Stockscreener 앱 받기
81.48
18.07%
12.47
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
ANI Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
ANI Pharmaceuticals: A High-Growth Biopharma Play with Rare Disease and Generics Synergy - AInvest
Assessing ANI Pharmaceuticals' (ANIP) Growth Trajectory in Rare Diseases and Generics Amid Strategic and Financial Headwinds - AInvest
ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates - MSN
Advanced analytics toolkit walkthrough for ANI Pharmaceuticals Inc.Free Buy Signal Based on Chart Analysis - Newser
ANI Pharmaceuticals Receives Buy Rating and Optimistic Price Target - timothysykes.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trend analysis for ANI Pharmaceuticals Inc. this weekFree Portfolio Diversification Stock Ideas - Newser
Will ANI Pharmaceuticals Inc. rebound enough to break evenFree Short Term Buy List With Stop Protection - Newser
Should I buy ANI Pharmaceuticals Inc. stock before earningsFree Weekly Watchlist of High Movers - Newser
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - MSN
ANI Pharmaceuticals Inc. stock daily chart insightsFree Fundamental + Technical Hybrid Stock Tips - Newser
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week High Following Earnings Beat - Defense World
ANI Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... By GuruFocus - Investing.com Canada
Published on: 2025-08-09 00:38:02 - Newser
ANI Pharmaceuticals Reports Record Growth in Q2 2025 - TipRanks
ANI Pharmaceuticals' Q2 2025: Unpacking Contradictions in Cortrophin Growth and Market Dynamics - AInvest
ANI Pharmaceuticals stock price target raised to $93 from $84 at H.C. Wainwright - Investing.com Canada
ANI: Q2 Earnings Snapshot - Norwalk Hour
Quantitative breakdown of ANI Pharmaceuticals Inc. recent moveFree Low Risk Buy Zone Opportunity Watch - Newser
ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright - TipRanks
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today - TradingView
ANI Pharmaceuticals Stock Surges After Buy Rating and Strong Price Target - StocksToTrade
ANI Pharmaceuticals Surges as Buy Rating Hits Market - timothysykes.com
Earnings call transcript: ANI Pharmaceuticals Q2 2025 earnings beat forecasts - Investing.com
Transcript : ANI Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
ANI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ani Pharmaceuticals stock hits 52-week high at 77.86 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42 - TipRanks
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
How high can ANI Pharmaceuticals Inc. stock goInvestment Position Summary with Timeframe Forecast - Newser
ANI Pharmaceuticals Boosts FY25 Outlook; Stock Up 7%Update - Nasdaq
ANI Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2025 Guidance Raised - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results - TradingView
ANI PHARMACEUTICALS INC SEC 10-Q Report - TradingView
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars - TradingView
ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast - MarketScreener
(ANIP) ANI Pharmaceuticals Expects 2025 Revenue Range $818M$843M, vs. FactSet Est of $791.5M - MarketScreener
Record Q4 net revenues up 53.1% YoY to $211.4mln, raises FY23 guidance. - AInvest
(ANIP) ANI Pharmaceuticals Expects Full-Year 2025 Adjusted EPS Range $6.98$7.35, vs. FactSet Est of $6.53 - MarketScreener
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $211.4M, vs. FactSet Est of $190.1M - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewswire
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.80 per Share, vs. FactSet Est of $1.41 - MarketScreener
ANI Pharma Stock Shoots Through The Roof On Friday: CEO's Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - Menafn
How ANI Pharmaceuticals Inc. stock performs during market volatilityRSI Divergence and Support Breakout Analysis - Newser
Earnings Preview For ANI Pharmaceuticals - 富途牛牛
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Envestnet Asset Management Inc. - Defense World
ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday - Defense World
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect - MSN
ANI Pharmaceuticals Q2 Earnings: What to Expect and How to Prepare - AInvest
Erythromycin Market Is Booming So Rapidly 2025-2032 -Ani - openPR.com
What analysts say about ANI Pharmaceuticals Inc. stockMaximize gains with timely market signals - Jammu Links News
How does ANI Pharmaceuticals Inc. compare to its industry peersBuild wealth steadily with smart stock selection - Jammu Links News
What is ANI Pharmaceuticals Inc. company’s growth strategyExplosive trading opportunities - Jammu Links News
What are the latest earnings results for ANI Pharmaceuticals Inc.High-profit trading signals - Jammu Links News
Is ANI Pharmaceuticals Inc. a good long term investmentBoost your wealth with consistent growth stocks - Jammu Links News
How many analysts rate ANI Pharmaceuticals Inc. as a “Buy”Get professional guidance for market timing - Jammu Links News
What drives ANI Pharmaceuticals Inc. stock priceUnlock daily trading alerts for profits - Jammu Links News
Allianz Asset Management GmbH Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
What is the dividend policy of ANI Pharmaceuticals Inc. stockRealize consistent double-digit growth - Jammu Links News
0.43%
0.47%
자본화:
|
볼륨(24시간):